Author

Atsushi Miyajima

Meiji Pharmaceutical UniversityPrimary ORCID profile (0000-0003-3176-5906 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Atsushi MiyajimaiD1 paper · Institute for Quantitative Biosciences, The University of Tokyo

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Atsuya Yamashita· 1 shared Haruyo Aoyagi· 1 shared Hideki AizakiiD· 1 shared Hiroshi SuemizuiD· 1 shared Hirotake Kasai· 1 shared Kaoru KobayashiiD· 1 shared Kohji MoriishiiD· 1 shared Kousho WakaeiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Atsuya Yamashita

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Vorapaxar and aripiprazole suppress hepatitis B virus replication through distinct host signaling pathways

Atsuya Yamashita, Hirotake Kasai, Haruyo Aoyagi, Kousho Wakae, Kaoru Kobayashi, Atsushi Miyajima, Yuichiro Higuchi, Hiroshi Suemizu, Ryo Fukushima, Masanori Isogawa, Takaji Wakita, Hideki Aizaki, Kohji Moriishi

This paper identifies vorapaxar and aripiprazole as inhibitors of HBV replication through distinct host signaling pathways, showing their potential as host-targeting antivirals.

bioRxiv · Aug 9, 2026 · PreprintPharmacology & Toxicology